BXP — Beximco Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- £162.83m
- £237.62m
- BDT39.27bn
- 92
- 98
- 77
- 99
Annual cashflow statement for Beximco Pharmaceuticals, fiscal year end - June 30th, BDT millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | BAS | BAS | BAS | BAS | BAS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 36.5 | 20.4 | 2.38 | 3.06 | 5.53 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 2,960 | 5,542 | 6,023 | 5,214 | 6,085 |
| Capital Expenditures | -4,545 | -2,275 | -2,558 | -2,939 | -2,710 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 35.1 | 328 | 33.8 | -4,741 | 93 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -4,510 | -1,947 | -2,525 | -7,680 | -2,617 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1,767 | -3,573 | -3,458 | 2,615 | -3,561 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 217 | 24.5 | 40.5 | 195 | -33 |